| Nov 7 |
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
|
| Nov 6 |
Allogene Therapeutics Q3 2024 Earnings Preview
|
| Nov 5 |
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunother...
|
| Nov 4 |
Allogene Therapeutics Announces Participation in November Investor Conferences
|
| Nov 1 |
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
|
| Oct 31 |
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
|
| Oct 30 |
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
|
| Oct 29 |
Allogene receives FDA RMAT designation for its metastatic renal cell carcinoma treatment
|
| Oct 29 |
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
|
| Oct 29 |
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
|
